JP2011513363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513363A5 JP2011513363A5 JP2010549127A JP2010549127A JP2011513363A5 JP 2011513363 A5 JP2011513363 A5 JP 2011513363A5 JP 2010549127 A JP2010549127 A JP 2010549127A JP 2010549127 A JP2010549127 A JP 2010549127A JP 2011513363 A5 JP2011513363 A5 JP 2011513363A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- carboxamide
- pyridin
- thiazole
- difluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, methyl Chemical group 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- OXMLPWDSSOSNEW-NSHDSACASA-N 5-amino-n-[4-[(3s)-3-aminopiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide Chemical compound C1[C@@H](N)CCCN1C1=CC=NC=C1NC(=O)C1=C(N)SC(C=2C(=CC=CC=2F)F)=N1 OXMLPWDSSOSNEW-NSHDSACASA-N 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000002018 overexpression Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 101150056413 Pim1 gene Proteins 0.000 description 4
- 108700020978 Proto-Oncogene Proteins 0.000 description 4
- 102000052575 Proto-Oncogene Human genes 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000009033 hematopoietic malignancy Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150054691 PIM3 gene Proteins 0.000 description 1
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108010083755 proto-oncogene proteins pim Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3335908P | 2008-03-03 | 2008-03-03 | |
| US61/033,359 | 2008-03-03 | ||
| PCT/EP2009/052506 WO2009109576A1 (en) | 2008-03-03 | 2009-03-03 | Pim kinase inhibitors and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513363A JP2011513363A (ja) | 2011-04-28 |
| JP2011513363A5 true JP2011513363A5 (https=) | 2013-11-07 |
| JP5412448B2 JP5412448B2 (ja) | 2014-02-12 |
Family
ID=41055566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549127A Active JP5412448B2 (ja) | 2008-03-03 | 2009-03-03 | Ｐｉｍキナーゼ阻害剤およびその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP2262802B1 (https=) |
| JP (1) | JP5412448B2 (https=) |
| KR (1) | KR20100120709A (https=) |
| CN (2) | CN104098559A (https=) |
| AR (1) | AR070531A1 (https=) |
| AU (1) | AU2009221134B2 (https=) |
| BR (1) | BRPI0909102A2 (https=) |
| CA (1) | CA2717388A1 (https=) |
| CL (1) | CL2009000483A1 (https=) |
| CO (1) | CO6290687A2 (https=) |
| EA (1) | EA201001412A1 (https=) |
| EC (1) | ECSP10010447A (https=) |
| ES (2) | ES2443496T3 (https=) |
| IL (1) | IL207865A0 (https=) |
| MA (1) | MA32135B1 (https=) |
| MX (1) | MX2010009739A (https=) |
| PE (1) | PE20091577A1 (https=) |
| TW (1) | TW200942536A (https=) |
| UY (1) | UY31679A1 (https=) |
| WO (1) | WO2009109576A1 (https=) |
| ZA (1) | ZA201006128B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| PL2344474T3 (pl) * | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| SI2432472T1 (sl) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| SG178986A1 (en) | 2009-09-08 | 2012-04-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| JP6161537B2 (ja) * | 2010-04-07 | 2017-07-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法 |
| WO2011136319A1 (ja) * | 2010-04-30 | 2011-11-03 | 国立大学法人 東京大学 | 抗がん剤 |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| US20130109682A1 (en) * | 2010-07-06 | 2013-05-02 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| UY33930A (es) * | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| EP2681197A1 (en) * | 2011-03-04 | 2014-01-08 | Novartis AG | Tetrasubstituted cyclohexyl compounds as kinase inhibitors |
| CA2834166A1 (en) | 2011-04-29 | 2012-11-01 | Amgen Inc. | Bicyclic pyridazine compounds as pim inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| CN102924446B (zh) * | 2011-08-11 | 2015-08-26 | 上海吉铠医药科技有限公司 | Pim激酶抑制剂及其制备方法与在制药中的应用 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US9173883B2 (en) * | 2012-05-21 | 2015-11-03 | Novartis Ag | Ring-substituted N-pyridinyl amides as kinase inhibitors |
| WO2014033631A1 (en) * | 2012-08-31 | 2014-03-06 | Novartis Ag | N-(3-pyridyl) biarylamides as kinase inhibitors |
| WO2014033630A1 (en) * | 2012-08-31 | 2014-03-06 | Novartis Ag | Novel aminothiazole carboxamides as kinase inhibitors |
| AU2013322736A1 (en) * | 2012-09-26 | 2015-02-26 | F. Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2019057821A1 (en) * | 2017-09-20 | 2019-03-28 | Lead Discovery Center Gmbh | COUMARIN DERIVATIVES, PROCESSES FOR PREPARING THEM AND USES THEREOF IN THE TREATMENT OF CANCER |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| KR20260008165A (ko) | 2019-02-12 | 2026-01-15 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| CN110452164B (zh) * | 2019-09-10 | 2022-07-22 | 上海皓鸿生物医药科技有限公司 | Pim447关键中间体的制备方法 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| TW200523252A (en) * | 2003-10-31 | 2005-07-16 | Takeda Pharmaceutical | Pyridine compounds |
| WO2007000582A1 (en) * | 2005-06-28 | 2007-01-04 | Takeda Cambridge Limited | Heterocyclic non-peptide gnrh antagonists |
| US20070117804A1 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| JP5103604B2 (ja) | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド |
| WO2008054702A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
| EP2078004B1 (en) * | 2006-10-31 | 2015-02-25 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| CA2679659C (en) * | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
-
2009
- 2009-02-27 PE PE2009000308A patent/PE20091577A1/es not_active Application Discontinuation
- 2009-02-27 UY UY031679A patent/UY31679A1/es not_active Application Discontinuation
- 2009-02-27 AR ARP090100684A patent/AR070531A1/es not_active Application Discontinuation
- 2009-03-02 TW TW098106739A patent/TW200942536A/zh unknown
- 2009-03-02 CL CL2009000483A patent/CL2009000483A1/es unknown
- 2009-03-03 EP EP09717066.6A patent/EP2262802B1/en active Active
- 2009-03-03 EP EP13154157.5A patent/EP2596790B1/en active Active
- 2009-03-03 WO PCT/EP2009/052506 patent/WO2009109576A1/en not_active Ceased
- 2009-03-03 CN CN201410286911.5A patent/CN104098559A/zh active Pending
- 2009-03-03 BR BRPI0909102A patent/BRPI0909102A2/pt not_active IP Right Cessation
- 2009-03-03 AU AU2009221134A patent/AU2009221134B2/en not_active Expired - Fee Related
- 2009-03-03 ES ES09717066.6T patent/ES2443496T3/es active Active
- 2009-03-03 EA EA201001412A patent/EA201001412A1/ru unknown
- 2009-03-03 JP JP2010549127A patent/JP5412448B2/ja active Active
- 2009-03-03 CA CA2717388A patent/CA2717388A1/en not_active Abandoned
- 2009-03-03 ES ES13154157.5T patent/ES2562306T3/es active Active
- 2009-03-03 MX MX2010009739A patent/MX2010009739A/es not_active Application Discontinuation
- 2009-03-03 KR KR1020107022008A patent/KR20100120709A/ko not_active Withdrawn
- 2009-03-03 CN CN200980115821.7A patent/CN102015701B/zh active Active
-
2010
- 2010-08-27 ZA ZA2010/06128A patent/ZA201006128B/en unknown
- 2010-08-30 IL IL207865A patent/IL207865A0/en unknown
- 2010-09-02 MA MA33140A patent/MA32135B1/fr unknown
- 2010-09-03 EC EC2010010447A patent/ECSP10010447A/es unknown
- 2010-09-07 CO CO10110544A patent/CO6290687A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513363A5 (https=) | ||
| EP2596790B1 (en) | Pim kinase inhibitors and methods of their use | |
| JP2013530199A5 (https=) | ||
| EP2861585B1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| JP5412519B2 (ja) | キナーゼ阻害剤としてのピコリンアミド誘導体 | |
| JP2017528475A5 (https=) | ||
| US20130109682A1 (en) | Cyclic ether compounds useful as kinase inhibitors | |
| RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
| RU2018138707A (ru) | Замещенные гетероарилом пиридины и способы применения | |
| JP2012528166A5 (https=) | ||
| JP2014527082A5 (https=) | ||
| JP2016513660A5 (https=) | ||
| CA2796967A1 (en) | Heterocyclic derivatives as alk inhibitors | |
| JP2013545823A5 (https=) | ||
| KR20170049604A (ko) | Bub1 억제제로서의 벤질 치환된 인다졸 | |
| JP2016006118A5 (https=) | ||
| JP2011504903A5 (https=) | ||
| JP2013199483A5 (https=) | ||
| JP2012510467A5 (https=) | ||
| JP2006505543A5 (https=) | ||
| JP2008528467A5 (https=) | ||
| JP2009543771A5 (https=) | ||
| JP7460639B2 (ja) | 血液癌を治療するための併用療法 | |
| JP2011521938A5 (https=) | ||
| JP2011506402A5 (https=) |